Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection

Journal of Heart and Lung Transplantation

Volumn 19, Issue 4, 2000, Pages 337-342

  Yamani, Mohamad H ^a   Starling, Randall C ^a   Pelegrin, David ^a   Platt, Luba ^a   Majercik, Mark ^a   Hobbs, Robert E ^a   McCarthy, Patrick ^a   Young, James B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FAILURE; LUNG ADENOCARCINOMA; MALE; NOCARDIA; PRIORITY JOURNAL;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MUROMONAB-CD3; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; STEROIDS; SURVIVAL RATE; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034041825     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(00)00059-0     Document Type: Article

References (28)

1. Thompson A.W. FK506 profile of an important new immunosuppressant. Transplant Rev. 4:1990;1-13.
2. Starzl T.E., Fung J.J., Demetris A.J., Venkataramanan R., Jain A. FK506 for human liver, kidney and pancreas transplantation. Lancet. 2:1989;1000-1004.
3. Fung J.J., Todo S., Tzakis A., et al. Conversion of liver allograft recipients from cyclosporine to FK506-based immunosuppression benefits and pitfalls. Transplant Proc. 23:1991;14-21.
4. Armitage J.M., Kormos R.L., Fung J., Lavee J., Fricker F.J. Preliminary experience with FK506 in thoracic transplantation. Transplantation. 52:1991;164-167.
5. Griffith B.P., Bando K., Hardesty R.L., et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation. 57:1994;848-851.
6. Armitage J.M., Kormos R.L., Griffith B.P., et al. A clinical trial of FK506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc. 23:1991;1149-1152.
7. Armitage J.M., Kormos R.L., Fung J.J., Starzl T.E. The clinical trial of FK506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc. 23:1991;3054-3057.
8. Armitage J.M., Kormos R.L., Morita S., et al. Clinical trial of FK506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg. 54:1992;205-211.
9. Rinaldi M., Pellegrini C., Martinelli L., et al. FK506 effectiveness in reducing acute rejection after heart transplantation A prospective randomized study. J Heart Lung Transplant. 16:1997;1001-1010.
10. Pham S.M., Kormos R.L., Hattler B.G., et al. A prospective trial of tacrolimus in clinical heart transplantation intermediate results. J Thorac Cardiovasc Surg. 111:1996;764-772.
11. Marcus N., Khaghani A., Burke M., Yacoub M., Banner N. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients. Transplant Proc. 30:(4):1998;1134-1135.
12. Meiser B.M., Uberfuhr P., Fuchs A., et al. Tacrolimus A superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant. 16:1997;795-800.
13. Reichart B., Meiser B., Vigano M., et al. European multicenter tacrolimus heart pilot study One-year results-European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant. 17:1998;775-781.
14. Meiser B.M., Schmidt D., Pfeiffer M., et al. Comparison of long-term effects between tacrolimus and cyclosporine based immunosuppression after heart transplantation. J Heart Lung Transplant. 18:1999;78.
15. Mentzer R.M., Jahania M.S., Lasley R.D. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. Transplantation. 65:(1):1998;109-113.
16. Zucker K., Rosen A., Tsaroucha A., et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunology. 5:1997;225-232.
17. Zucker K., Tsaroucha A., Olson L., et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit. 21:(1):1999;35-43.
18. Meiser B.M., Uberfuhr P., Fuchs A., et al. Single-center randomized trial comparing tacrolimus and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant. 17:1998;782-788.
19. Gilbert E.M., Eiswirth C.C., Renlund D.G., et al. Use of orthoclone OKT3 monoclonal antibody in cardiac transplantation early experience with rejection prophylaxis and treatment of refractory rejection. Transplant Proc. 19:(Suppl 1):1987;45-53.
20. Kremer A.B., Barnes L., Hirsch R.L., et al. Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments. Transplant Proc. 19:(Suppl 1):1987;54-57.
21. Rogers K.R., Sinnott J.T., Ferguson J.E. Using OKT3 to reverse cardiac allograft rejection. Heart Lung. 18:1989;490-496.
22. Sweeney M.S., Macris M.P., Frazier O.H., et al. The treatment of advanced cardiac allograft rejection. Ann Thorac Surg. 46:(4):1988;378-381.
23. Haverty T.P., Sanders M., Sheahan M. OKT3 treatment of cardiac allograft rejection. J Heart Lung Transplant. 12:(4):1993;591-598.
24. Cantarovich M., Latter D.A., Loertscher R. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Clin Transplant. 11:(4):1997;316-321.
25. Hosenpud J.D., Norman D.J., Pantely G.A., Cobanoglu A.M., Starr A. OKT3-induced hypotension in heart allograft recipients treated for steroid-resistant rejection. J Heart Transplant. 8:(2):1989;159-165.
26. Wagner F.M., Reichenspurner H., Uberfuhr P. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation. J Heart Lung Transplant. 13:(3):1994;438-442.
27. O'Connell J.B., Renlund D.G., Gay W.A., et al. Efficacy of OKT 3 retreatment for refractory cardiac allograft rejection. Transplantation. 47:1989;788-792.
28. O'Connell J.B., Renlund D.G., Hammond E.H., et al. Sensitization to OKT3 monoclonal antibody in heart transplantation correlation with early graft loss. J Heart Lung Transplant. 10:1991;217-222.